Cat. No. 2196
Chemical Name: α-Amino-5-carboxy-3-methyl-2-thiophe
Biological ActivityPotent metabotropic glutamate mGlu1 receptor antagonist (IC50 = 6.3 μM at rat mGlu1a). Displays ≥ 40-fold selectivity over other receptors: mGlu5, mGlu2, mGlu4a (IC50 > 300 μM), NMDA and AMPA (IC50 = 250 μM). Neuroprotective in cultured murine cortical cells and rat hippocampal slice cultures in vitro. Reduces the volume of ischemia-induced brain infarcts in rats following systemic administration in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Constantino et al (2004) Stereoselective synthesis and preliminary evaluation of (+)- and (-)-3-methyl-5-carboxy-thien-2-yl-glycine (3-MATIDA): identification of (+)-3-MATIDA as a novel mGluR1 competitive antagonist. Il Farmaco 59 93. PMID: 14871500.
Cozzi et al (2002) Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity? Neuropharmacology 43 119. PMID: 12213266.
Moroni et al (2002) The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death. Neuropharmacology 42 741. PMID: 12015200.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses 3-MATIDA from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 3-MATIDA, supplier, Potent, selective, mGlu1, mGluR1, antagonists, mGlur, Group, I, Receptors, mGlu5, mGluR5, Glutamate, Metabotropic, Tocris Bioscience, Glutamate (Metabotropic) Group I Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Negative allosteric modulator at mGlu7; brain penetrantVU 0409551
Selective mGlu5 positive allosteric modulator; brain penetrant and orally bioavailable
October 30 - November 3, 2016
Boston, MA, USA